Mario Rivera-Chavarria on LinkedIn: 21st Clinical Trials Nexus 2024 (2024)

🚨 Scoop: GHO puts Velocity Clinical Research on the blockSecond scoop in three weeks and hopefully many more to come!GHO Capital is preparing to bring clinical trial services provider Velocity Clinical Research to market, sources told me.Why it matters:A recent surge in biotech funding will finance increased R&D, increasing demand for clinical trial site management services like VCR's.Get more info below 👇 #privateequity #clinicaltrials #clinicalresearch #lifesciences

18

CROs: Unlocking Efficiency with DCT Platforms! As the pharmaceutical industry continues to evolve, so do the challenges faced by Contract Research Organizations (CROs). But fret not, fellow professionals, for there's a game-changer in town: Digital Clinical Trial (DCT) platforms!🔍 Efficiency at its Finest: Gone are the days of cumbersome paperwork and manual data entry. With DCT platforms, CROs can streamline processes, from patient recruitment to data collection and analysis, saving both time and resources.💡 Insights that Matter: With robust analytics and real-time reporting capabilities, DCT platforms empower CROs to gain actionable insights promptly. Say hello to informed decision-making and optimized trial outcomes!🌐 Global Reach, Local Impact: Whether your trials span across continents or focus on specific regions, DCT platforms offer seamless collaboration and compliance with diverse regulatory requirements, ensuring smooth sailing throughout the trial lifecycle.💼 Empowering Collaboration: By fostering collaboration among stakeholders, including sponsors, investigators, and patients, DCT platforms facilitate communication, enhance transparency, and ultimately drive success in clinical trials.👉 Book Your Demo with Milo: Ready to witness the power of DCT firsthand? Book a personalized demo with our cutting-edge platform, Milo, designed specifically to revolutionize clinical trial operations. Let's explore how Milo can elevate your CRO's trials to new heights!Connect with us today to schedule your demo. Together, let's pave the way for innovation in clinical research! #ClinicalResearch #DCT #CROs #Innovation #Efficiency #Collaboration

12

How top pharma are constructing their next model of clinical development.According to Grandview Research, the hybrid and decentralized clinical trial (DCT) market will be worth more than 12 billion dollars by 2030.Hear from four top minds across pharma and discover what the next model of clinical conduct looks like. Get the latest insights from Gilead Sciences, Veeva, Syneos Health & Medable now!For more info: https://lnkd.in/g6MAEZGu#clinicaldevelopment #pharmaceuticalindustry #pharmainnovation #industryinsights #clinicaltrials #decentralizedclinicaltrials #hybridclinicaltrial

16

Citeline partnered with Pharma Ignite for a roundtable to discuss the pros and cons of basing clinical trials in today’s European landscape.The free report covers:- The factors making the US a key clinical trial location, despite recent changes to European systems.- A critical element that gives clinical trials in Europe an edge over the United States.- The particular advantages offered by Eastern Europe as a clinical trial destination.- The impacts of new regulatory and process changes in Europe.Varying financial incentives for conducting clinical trials across European countries.https://lnkd.in/eS7a3yMp#clinicaltrials #europe #pharma

19

The value Chain of Digital TherapeuticsEarlier this month, TechToMed organized the 3rd edition of DTx France© in Paris. Karine Soulat shares her takeaways from this insightful day. Digital therapeutics (DTx) are at the forefront of healthcare innovation, using software to provide therapeutic interventions based on clinical evidence. The value chain of DTx includes several essential steps, from design to market entry, through clinical validation and reimbursem*nt. This value chain is enriched with elements from discussions and presentations from DTx France, which gathered 170 participants in Paris and more participants online.Read on to dive into the 4 phases of the value chain of DTx:1. Content of DTx Software2. Regulatory Requirements3. Market Access4. Commercialization Model and Adoptionhttps://lnkd.in/d_VKCNs8#DTx #digitaltherapeutics #adoption #reimbursment #businessmodel #regulatory #innovation

17

1 Comment

The clinical trial landscape is rapidly evolving. Lloryn Hubbard, Les Enterline and Cristina Nieto outline 4️⃣ key trends shaping the industry today:🌎 Expanded focus on patient diversity📈 Rise in functional service provider (FSP) solutions and hybrid FSP/full-service outsourcing (FSO)📜 Increased protocol and regulatory complexity📱 Leveraging technology solutions for efficiency and cost reductionOur experts discuss more in Contract Pharma. » https://bit.ly/3YkwBFC

169

2 Comments

🚨 Are you currently facing a drug shortage for your trial? Technology can help! Drug shortages pose a significant challenge in the ever-evolving landscape of clinical trials, but technology can serve as a vital safety net, safeguarding patients, companies, and financial interests alike!Last week at Clinical Trial Supply Event Series New England, N-SIDE's Jake Levine and Maxime Derep emphasized the critical role of technology in mitigating these risks and ensuring patient safety. Let's empower clinical trial supply managers to leverage technology and drive positive change in the industry 👇

10

The clinical trial supplies market was estimated at $3.9 billion in 2023 and is projected to reach $6.3 billion by 2028! Priyanka Bhendale of MarketsandMarkets™ sharessome of the anticipated developments and trends for the clinical trial supply chain. https://lnkd.in/eWjzrj8r #clinicaltrials #clinicalsupply #marketoutlook

4

Check out our latest Q&A published in Contract Pharma, where One2Treat’s CEO, Sébastien Coppe, PhD, shares his expertise on the evolving landscape of clinical research and its pivotal role supporting sponsor's needs.💡 Patient-centricity in clinical trials is becoming a critical focus, with an emphasis on integrating patient perspectives from trial design to market access.💡 Innovative statistical methodologies are revolutionizing clinical trials, enhancing patient-centricity and improving trial efficiency.💡 The increasing complexity of clinical trials and evolving regulatory landscapes open new opportunities for digital innovation, allowing to align multiple important stakeholders (patients, sponsor, regulatory agencies and payers) as early as clinical trial design.Read the full Q&A to learn how One2Treat is leading the way in transforming clinical trials with a patient-centered approach.👉 https://lnkd.in/eiPxqDjG#ClinicalTrials #PatientCentricity #Innovation

26

3 Comments

What were the highlights of the recent clinical trial supply conferences N-SIDE attended?We haven't finished listing them yet! From reconnecting with familiar industry peers to engaging with new prospects seeking stress-free and sustainable clinical supply planning, our N-SIDE Life Sciences team had a fulfilling experience at conferences across Europe and the US over the past few months! However, one may particularly stand out: the co-presentation in Barcelona featuring our experts Amaury Jeandrain and Sasha Van Heuverswyn alongside our esteemed partner Sanofi, represented by Arnaud DOURLENS, Head of Clinical Supply Operations. We shared how innovation and data processing combined with a strong culture of performance allowed to double from 35 to 70% the proportion of drug ultimately dispensed to patients and a reduction by up to 50% in the total quantities of drugs required to conduct a trial. This resulted in significant improvements notably in patient service levels, cost savings, and reduced carbon footprint, ultimately enhancing Sanofi's overall performance in clinical trial supply.N-SIDE revolutionizes clinical trials, drastically reducing timelines and enhancing efficiency. Connect with us at our upcoming conferences and discover how we are transforming the industry 👉 https://lnkd.in/e5SgGCFF#LifeSciences #Pharma #Biotech #ClinicalTrials #Conference

55